Page 143 of 282: studies 1,421 to 1,430 of 2,815, newest first. Back to the LSD overview
Orvosi hetilap September 13, 2026 Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
The Journal of Physical Chemistry B September 12, 2026 Cong Zhang, Mingqi Li, Jing Ma et al.
Abstract Precise control over the thermodynamics and kinetics of receptor–ligand interactions is pivotal for manipulating physiological processes and developing targeted therapies. However, conventional pharmacological approaches often lack the spatiotemporal precision required for noninvasive in vivo modulation. Terahertz (THz) technology offers a promising alternative by using nonionizing...
Scientific Reports September 11, 2026 Pedro J. Teixeira, Aaron D. Cherniak, Matthias Forstmann
While some studies suggest that psychedelic use may be linked to positive environmental attitudes and health behaviors, the relationship between these factors remains underexplored. This study investigates the associations between lifetime use of psilocybin and LSD, environmental attitudes, and dietary behaviors using data from two UK birth cohort studies: the 1958 National Child Development...
medRxiv September 10, 2026 Mori Krantz, Mark C. Haigney, Mary Ross Southworth et al. preprint
Background: Several Schedule I substances have demonstrated potential benefits for refractory psychiatric conditions and addiction. Some have been legalized at the state level, while others like kratom (mitragynine) are available over-the-counter in some states and illegal in others. A recent presidential executive order directs certain federal agencies to accelerate development and facilitate...
The International Journal of Neuropsychopharmacology September 9, 2026 Noemi Nicosia, Jessica Mingardi, G Terribile et al.
Abstract Background Chronic stress is a key risk factor for major depressive disorder (MDD), one of the leading causes of disability worldwide1. Despite available pharmacological therapies, treatment-resistant depression (TRD) remains a clinical challenge. Hallucinogens such as ketamine and serotonergic psychedelics including psilocybin and lysergic acid diethylamide (LSD)2 show rapid...
The International Journal of Neuropsychopharmacology September 9, 2026 Gabriella Gobbi
Abstract Background While the monoaminergic hypothesis has long dominated the treatment of mood disorders, its limitations have prompted the exploration of alternative mechanisms. Early work by Skolnick et al. (1996) demonstrated that chronic antidepressant treatment induces adaptive changes in N-methyl-D-aspartate (NMDA) receptors, suggesting glutamatergic signaling as a convergent pathway in...
The International Journal of Neuropsychopharmacology September 9, 2026 B Richardson, J O'Byrne, V Bruno et al.
Abstract Background Psychedelics induce altered states of consciousness (AOC) with profound perceptual, cognitive, and emotional shifts, often linked to positive therapeutic outcomes. Although serotonergic psychedelics such as psilocybin, LSD, and 5-MeO-DMT share receptor targets, they differ in behavioral and neural effects. How these compounds alter cortical dynamics relative to other...
The International Journal of Neuropsychopharmacology September 9, 2026 J Vieira-Andrade, I Marques, M Brito
Abstract Background Serotonin 2A receptor (5-HT2AR) agonists play a crucial role in multiple cognitive processes, namely executive functions, learning and memory. Owing partly to this, psychedelics such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline and ayahuasca might be valuable adjuvants in improving memory deficits and language impairment. Thanks to...
Zenodo (CERN European Organization for Nuclear Research) September 7, 2026 Christian Alexander Brown preprint
This research essay/article argues that cannabis can reasonably be described as psychedelic in a phenomenological sense, even though it is not pharmacologically classified as a classic serotonergic psychedelic such as LSD or psilocybin. The central distinction is between pharmacology and phenomenology: THC acts primarily through the endocannabinoid system, especially CB1 receptor signaling, yet...
Cureus September 2026 Robert B. Raffa
An Executive Order signed in April 2026 directed US federal agencies to expedite development and review pathways for psychedelic and psychedelic-adjacent (such as ibogaine) therapies. The FDA issued Commissioner's National Priority Vouchers to psilocybin developers, and cleared the investigational new drug (IND) application for noribogaine hydrochloride for alcohol use disorder. These...